<DOC>
	<DOCNO>NCT01490060</DOCNO>
	<brief_summary>The goal clinical research study learn different dos fosaprepitant may effect ifosfamide-based chemotherapy absorb body . Researchers also want learn fosaprepitant help control prevent delay nausea and/or vomit may cause chemotherapy . The safety drug also study . Fosaprepitant design block natural substance brain cause nausea vomit . This may help prevent and/or control nausea vomit cause chemotherapy .</brief_summary>
	<brief_title>Fosaprepitant Patients Receiving Ifosfamide-based Regimen</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , receive fosaprepitant 21-day chemotherapy cycle . You randomly assign ( toss dice ) 1 2 study group , 2 division : - If Group A1 , receive fosaprepitant Day 1 Cycle 1 . - If Group A2 , receive fosaprepitant Day 1 Cycle 2 . - If Group B1 , receive fosaprepitant Days 1 4 Cycle 1 . - If Group B2 , receive fosaprepitant Days 1 4 Cycle 2 . You study staff know group division assign . Each time receive drug , receive vein 20-30 minute . You also receive ifosfamide-based chemotherapy prescribe doctor , well standard drug prevent nausea vomiting ( ondansetron , lorazepam , diphenhydramine , promethazine ) . You sign separate consent form describe treatment detail , along risk . You receive dexamethasone chemotherapy , every day 5 day , help prevent nausea vomit . Before chemotherapy cycle , give study diary . Each day , record side effect may . You bring study diary every study visit study staff review . Study Visits : Before cycle receive fosaprepitant , follow test procedure perform : - You physical exam . - Your vital sign , weight , performance status record . - You fill questionnaire screening . - You ask drug may take . Be sure tell study doctor drug ( include vitamin , herbal product , nutritional supplement ) , drugs/substances cause side effect take time fosaprepitant . - Blood ( 5 teaspoon ) draw routine test . Blood ( 1 teaspoon ) also draw 2 time week Cycles 1 2 routine test . Pharmacokinetic Testing : On Days 1 4 Cycles 1 2 chemotherapy , blood sample ( 2 teaspoon time ) drawn pharmacokinetic ( PK ) testing , possible . PK test measure amount study drug body different time point . The blood drawn receive ifosfamide , end infusion , 4 time 24 hour infusion . Length Study : You may receive 6 cycle chemotherapy ( 5 cycle fosaprepitant ) . You longer able take study drug disease get bad intolerable side effect occur . Your participation study complete end-of-study visit . End-of-Study Visit : About 3 week last dose fosaprepitant , return end-of-study visit . At visit , follow test procedure perform : - You physical exam . - Your vital sign , weight , performance status record . - You fill questionnaire screening . - You ask drug may take . - Blood ( 5 teaspoon ) draw routine test . This investigational study . Fosaprepitant FDA approve commercially available combination drug prevention nausea vomit may cause chemotherapy . It investigational study fosaprepitant may affect drug level ifosfamide blood many dos give . Up 36 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients sarcoma locally advance , high risk relapse metastatic treatment doxorubicin plus ifosfamide ( AI ) AI vincristine ( VAI ) indicate . 2 . Must 1865 year age . 3 . Male Females child bear potential must use acceptable method birth control include oral contraceptive , spermicide either condom , diaphragm cervical cap , u intrauterine device ( IUD ) abstinence . 4 . Adequate hematologic ( ANC &gt; /= 1500/mm^3 , platelet count &gt; /= 100,000/mm^3 ) , renal ( serum creatinine &lt; /= 1.5 mg/dL ) , hepatic ( serum bilirubin count &lt; /= 1.5 x normal SGOT SGPT &lt; /= 3 x normal ) function . 5 . Karnofsky Performance Status &gt; /= 60 % 6 . Signed informed consent form . 7 . Patients require read understand English comply protocol requirement . 1 . Pregnant lactating woman . 2 . Patients comorbid condition render patient high risk treatment complication . 3 . Known allergy fosaprepitant active component . 4 . Patient uncontrolled angina , congestive heart failure ( New York Heart Association &gt; class II know ejection fraction &lt; 40 % ) , uncontrolled cardiac arrhythmia hypertension , acute myocardial infarction within 3 month . 5 . Patient active seizure disorder . ( Patients previous history seizure disorder eligible study , evidence seizure activity , free antiseizure medication previous 5 year ) . 6 . Prior surgery radiotherapy ( RT ) within 2 week study entry . 7 . Psychological , social , familial , geographical reason would prevent schedule visit followup . 8 . Patients receive medication preexist nausea/vomiting exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>fosaprepitant</keyword>
	<keyword>Ifosfamide-based Multi-day Chemotherapy</keyword>
	<keyword>Chemotherapy-induced nausea vomit</keyword>
	<keyword>CINV</keyword>
	<keyword>multi-day chemotherapy regimen</keyword>
	<keyword>antiemetic</keyword>
	<keyword>adverse effect</keyword>
	<keyword>doxorubicin plus ifosfamide</keyword>
	<keyword>AI</keyword>
	<keyword>AI vincristine</keyword>
	<keyword>VAI</keyword>
	<keyword>aprepitant</keyword>
	<keyword>prevention</keyword>
	<keyword>nausea</keyword>
	<keyword>vomit</keyword>
	<keyword>emetogenic chemotherapy</keyword>
</DOC>